Novel Dosage Form

A pharmaceutical dosage form for oral administration comprising a sanglifehrin as active ingredient in which the sanglifehrin active ingredient is protected from acid degradation in the stomach environment following oral administration, wherein protection of the active ingredient is achieved by provision of a layer of enteric coat, said enteric coat being stable in the acid environment of the stomach, and adapted to release the active ingredient in the higher pH environment of the small intestine.